ongoing

Stroke is a major contributor to death and disability globally, and its burden will increase dramatically with ageing populations. The trajectories and determinants of cognitive impairment and functional outcomes after stroke are incompletely understood, particularly in lower income countries.

The PROSPECT platform will prospectively evaluate outcomes after stroke internationally, with integration of interventions and randomized controlled trials (RCTs) to improve cognitive and functional outcomes.

The co-primary outcomes of PROSPECT are cognitive and functional impairment.

The secondary outcomes include: quality of life, depression, fatigue, mortality, recurrent stroke and cardiovascular events, and other adverse events.

Participants will be followed for 5 years post stroke.

The platform will be used for sub-studies including imaging, genetic and biomarker analysis, and for embedded RCTs.

Study Type

Observational

Study Design

Prospective global platform

NO. of Countries

11

NO. of Sites

13

NO. of Participants

10,000

Study Period

2022 - 2033

Sponsor

PHRI

Hamilton Health Sciences New Investigator Fund

World Stroke Organization

Bayer

Back To Top